Overview
Alcohol use disorder (AUD) is the second highest preventable cause of death in France. Only 3% of patients are prescribed approved drugs for reducing alcohol consumption or maintenance of abstinence. Increasing evidence supports the efficacy of psychotherapies such as cognitive and behavioral therapies (CBT) in AUD. However, some patients are resistant to CBT and the positive effects of CBT could wane over time, resulting in mid- and long-term relapses. Mindfulness practice is increasingly widespread in the United States and its efficacy in various fields appears very promising. The study investigators hypothesize that the Mindfulness Based Relapse Prevention (MBRP) program will be more efficient than a relaxation/meditation without guidance control program in AUD.
Eligibility
Inclusion Criteria:
- Having a moderate to severe alcohol use disorder according to DSM 5 criteria.
- The last drink must have been consumed at most in the last 60 days before the pre-inclusion visit. The patient must have had at least 1 HDD during the last drinking period
Exclusion Criteria:
- Severe depression (Beck Depression Inventory> 30)
- Schizophrenic disorder,
- Current maniac or hypomaniac episode,
- Patient with dementia or severe cognitive impairment that would prevent him/her from following the course of a session, as judged by the clinician.
- Insufficient French understanding to complete the questionnaires
- Pregnant or breastfeeding woman
- Absence of social security regimen
- Other mindfulness-based structured therapies
- Refusal to sign the written consent. • The patient is under safeguard of justice or state guardianship